|Awarded On||November 19, 2015|
|Title||Targeting the undruggable: a first-in-class inhibitor of the HIF-2 transcription factor|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||James Brugarolas|
|Cancer Sites||Kidney and Renal Pelvis|
Kidney cancer is particularly prevalent in Texas. One third of patients present with metastasis and another third will develop metastases. In the metastatic setting, kidney cancer is incurable. Recent discoveries about the biology of kidney cancer have led to 7 new drugs. These drugs extend life expectancy, but do not cure. The drugs target two classes of kidney cancer drivers, growth factors and kinases. However, suitable drug targets have been exhausted and there are no good strategies to target proteins in other classes. The most important driver of kidney cancer, the HIF-2 complex, belongs to a class of proteins, transcription factors, that have traditionally been considered “undruggable...